

samumed news

November 2018

Osteoarthritis (OA) Program Update



- FDA has granted an end of phase 2 meeting for SM04690
- We have initiated a phase 2, multiple injection safety and tolerability study on SM04690

Corporate News



- We have hired the following senior position:
 - Mark Fineman, SVP Clinical Development
- Our CEO, Osman Kibar, presented at the Exponential Medicine Congress on pioneering longevity